Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


German artificial heart project to aid reimbursement:

This article was originally published in Clinica

Executive Summary

In an effort to increase awareness of new therapies developed to treat heart problems, the German medical device industry association, BVMed, has set up a new ventricular assist services/artificial heart project group, VAD/Kunstherz. Major aims of the group include introducing therapeutic possibilities to doctors and disseminating information to medical decision makers. "Numerous lives could thus be saved because there are not enough donor hearts available in Germany and almost a third of patients awaiting transplantation die before one becomes available," says the association. BVMed hopes that this initiative will speed up the entry of such therapies into the catalogue of reimbursable procedures under the new diagnosis related groups (DRG) system. A study recently published in the Journal of the American College of Cardiology said that heart transplant patients who receive implantable mechanical heart pumps until donor hearts become available have a better chance of survival and lower post transplant death rates than those relying on medication.

You may also be interested in...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts